BPC 157 is a recurring topic in our peptide coverage. This hub collects every article tagged BPC 157, newest first, each evidence-graded and tied to real, verifiable sources.
Wound healing is one of the few peptide areas with genuine human controlled-trial data — but it is narrow, topical, and concentrated in chronic wounds. A clinical-editorial ranking of GHK-Cu, thymosin β4, LL-37 and BPC-157 by what the evidence actually supports in 2026.
An evidence-graded review of the peptides marketed for wrist sprains, tenosynovitis, TFCC tears and carpal tunnel syndrome. The honest 2026 verdict: no human RCT — indeed essentially no human data of any kind — exists; the case is entirely preclinical (rat tendon and sciatic-nerve models), and conventional care has the far stronger human evidence.
A clinical, evidence-first ranking of the peptides most promoted for healing surgical incisions and preventing scars — separating genuine human topical-wound data from animal-only signals and marketing.
Tendon is the single best-studied musculoskeletal target for repair peptides — yet no human RCT exists for any peptide in any tendinopathy. We rank BPC-157, TB-500/thymosin β-4 and GHK-Cu strictly by the real evidence.
A clinical, evidence-first look at the peptides pitched for rotator-cuff tears, labral injury and shoulder tendinopathy — BPC-157, TB-500/thymosin β-4, and GHK-Cu — and why all three are graded C (preclinical only) for the shoulder.
An evidence-graded look at the peptides marketed for rotator-cuff tears and repair recovery — BPC-157, TB-500/Thymosin β4 and GHK-Cu — separating a single unpublished rat abstract and animal mechanism from anything resembling human proof.
An evidence-first ranking of the peptides studied for rheumatoid and autoimmune arthritis — thymosin alpha-1, BPC-157, ARA-290 and KPV — separating real human data from preclinical promise, and flagging the immune-flare risk in a joint-destroying disease.
A clinical, evidence-graded ranking of the peptides marketed for post-surgical recovery — thymosin alpha-1, thymosin β4/TB-500, GHK-Cu and BPC-157 — separating the one with human surgical RCT data from the rest, which are topical, negative, or preclinical only.
An evidence-graded review of the peptides marketed for osteoarthritis and joint degeneration. The honest 2026 verdict: the strongest human data belongs not to any joint-repair peptide but to GLP-1 metabolic drugs that relieve knee-OA pain by removing mechanical load.
A clinical, evidence-graded ranking of the peptides studied for nerve injury and neuropathy — ARA-290, Cerebrolysin, BPC-157 and Cortagen — separating genuine human RCT data from animal-only signal.
An evidence-graded review of the peptides marketed for whiplash and neck soft-tissue injury. The honest 2026 verdict: there is no human evidence — no RCT, cohort, or registered trial — for any peptide in the cervical spine; the strongest case tops out at rat ligament and tendon models.
A clinical, evidence-graded review of the peptides marketed for hamstring pulls, calf and quad strains, and muscle tears — where the animal data are genuinely muscle-specific, and why no completed human trial yet proves any of them heals a strain.
An evidence-first review of the peptides men buy for muscle, testosterone, libido and recovery — graded honestly by human data, with the FDA and WADA status that marketing leaves out.
A clinical, evidence-first review of the peptides marketed for long COVID (PASC) fatigue — thymosin alpha-1, elamipretide (SS-31), aviptadil and BPC-157. The blunt headline: no peptide has a positive long-COVID trial.
A clinical, evidence-graded review of the peptides marketed for sprains, MCL tears and ACL injury — where the rat data are genuinely ligament-specific, and why no human trial yet proves any of them heals a torn ligament.
An evidence-first ranking of the peptides studied for the intestinal barrier — teduglutide, larazotide acetate, BPC-157 and KPV — separating one Grade-A drug for a different condition from failed, abandoned or preclinical-only 'leaky gut' claims.
An evidence-graded review of the peptides marketed for meniscus tears, ligament sprains, tendinopathy and cartilage wear. The honest 2026 verdict: no peptide has a placebo-controlled human knee trial — the strongest case is preclinical (rat surgery models) plus one uncontrolled human case series.
A clinical, evidence-graded review of the peptides marketed for joint health and joint pain — BPC-157, TB-500/thymosin β-4, GHK-Cu and ARA-290 — ranked honestly by the strength of their human vs preclinical data.
An evidence-graded review of the peptides marketed to 'injury-proof' tendons and ligaments. The honest 2026 verdict: prevention is the single most speculative claim in the peptide literature — no human prevention RCT, and no controlled animal prevention study, exists for any candidate.
An evidence-first ranking of the peptides studied for inflammaging and chronic low-grade inflammation of aging — thymosin alpha-1, ARA-290, thymalin, BPC-157 and KPV — separating real human trials from preclinical promise, and flagging the bidirectional immune risk.
BPC 157 is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged BPC 157, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.